GDRX logo

GDRX
GoodRx Holdings Inc

5,940
Mkt Cap
$808.48M
Volume
3.23M
52W High
$5.81
52W Low
$1.77
PE Ratio
30.29
GDRX Fundamentals
Price
$2.55
Prev Close
$2.36
Open
$2.36
50D MA
$2.20
Beta
1.37
Avg. Volume
1.27M
EPS (Annual)
$0.0853
P/B
1.41
Rev/Employee
$1.14M
$1,248.38
Loading...
Loading...
News
all
press releases
GoodRx (NASDAQ:GDRX) Trading 8.7% Higher - Should You Buy?
GoodRx (NASDAQ:GDRX) Shares Up 8.7% - What's Next...
MarketBeat·8h ago
News Placeholder
More News
News Placeholder
GoodRx Expands Offerings to Now Include Ozempic Pill for Type 2 Diabetes Patients
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisks Ozempic pill (oral semaglutide...
Business Wire·17h ago
News Placeholder
Hims & Hers Expands Digital-First Access to Personalized Healthcare
HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.
Zacks·3d ago
News Placeholder
Sandisk and Whirlpool have been highlighted as Zacks Bull and Bear of the Day
Sandisk shines as AI-driven storage demand fuels growth, while Whirlpool struggles with weak earnings, margin pressure and a persistent stock downtrend.
Zacks·5d ago
News Placeholder
Tempus AI Nears Profitability as Operating Leverage Emerges
TEM nears profitability as gross profit surges and EBITDA turns positive, but persistent GAAP losses keep focus on long-term operating leverage.
Zacks·7d ago
News Placeholder
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
OPRX edges past GDRX with AI-driven platform momentum, stronger estimates and lower valuation despite near-term revenue headwinds.
Zacks·8d ago
News Placeholder
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
GoodRx Holdings, Inc. (Nasdaq: GDRX) (GoodRx or the Company), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after...
Business Wire·14d ago
News Placeholder
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
Zacks·16d ago
News Placeholder
GoodRx Now Offers Access to Wegovy HD at $399 Per Month Self-Pay Price
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy HD (semaglutide) injection 7.2 mg is now available to eligible...
Business Wire·17d ago
News Placeholder
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern?
OptimizeRx lowers 2026 revenue forecast on shifting pharma spend and managed services drag, but signals recovery ahead and stronger EBITDA expectations.
Zacks·18d ago
<
1
2
...
>

Latest GDRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.